Characterization of the KRas G12D-inhibitor interactions by differential HDX-MS and molecular dynamics simulations
Hydrogen-deuterium exchange (HDX) combined with mass spectrometry (MS) is a powerful technique for studying changes in protein structure and dynamics upon ligand binding. Protein-ligand complexes can result in increased protection of peptide-bond amides in HDX indicating protein structure stabilizat...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Computational and Structural Biotechnology Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037025003307 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Hydrogen-deuterium exchange (HDX) combined with mass spectrometry (MS) is a powerful technique for studying changes in protein structure and dynamics upon ligand binding. Protein-ligand complexes can result in increased protection of peptide-bond amides in HDX indicating protein structure stabilization. We have characterized the interaction of small-molecule inhibitors towards the KRas G12D oncoprotein by intact-protein and bottom-up HDX-MS, in combination with molecular dynamics (MD) simulations. Significant differences in HDX protection were detected upon inhibitor binding in the flexible switch-II pocket of the protein. MD simulations of the free and inhibitor-bound KRas G12D proteins also revealed changes in the hydrogen bond network of backbone amides in the switch-II region upon inhibitor binding, explaining the observed HDX protection changes. We have proposed simple semi-empirical metrics which relate changes in HDX-MS experimental values and observed in MD simulations changes in individual backbone hydrogen-bonds between free- and ligand-bound protein states. This combined HDX-MS and MD approach provides an atomistic picture of changes in the KRas G12D secondary structure upon ligand binding and may be a useful tool for future drug design efforts. |
|---|---|
| ISSN: | 2001-0370 |